Authors
Latest:
Dr. Bloom Explains Situations Requiring HER2 RetestingDr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting
Latest:
Focal Therapy Evolves Into More Precise Treatment in Prostate CancerHistorically, the management of localized prostate cancer has centered on removal or ablation of the entire gland with either extirpative surgery or radiation. However, the subsequent unacceptable adverse events profile can be devastating and life altering for many patients.
Latest:
Voice Recognition Systems Save Time and MoneyDue to a variety of factors, today’s oncologists face multiple challenges in collecting, managing, and sharing their patients’ health data.
Latest:
Dr. Carson Discusses Mogamulizumab as Potential Treatment for CTCLKenneth R. Carson, MD, assistant professor, Division of Oncology, Washington University, discusses mogamulizumab as a potential treatment for patients with relapsed or refractory cutaneous T cell lymphoma (CTCL).
Latest:
Dr. Mouw on the Role of Radiation Therapy in Prostate CancerKent W. Mouw, MD, PhD, co-director, Bladder Cancer Center, assistant professor, Radiation Oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of radiation therapy in prostate cancer.
Latest:
Dr. Adelson on Bortezomib plus Fulvestrant for HR+ Breast CancerKerin Adelson, MD, Assistant Professor of Medicine, Hematology, and Medical Oncology at the Icahn School of Medicine at Mount Sinai, explains the results of a phase II clinical trial comparing fulvestrant alone with bortezomib plus fulvestrant for the treatment of hormone receptor-positive metastatic breast cancer.
Latest:
Screening and Management: Distress and the Nurse Navigator, Part IICancer and its treatment creates or aggravates psychosocial distress, while unresolved physical and practical problems can also add to the distress of patients attempting to complete their treatment and recovery.
Latest:
Taking Trial Data to the Clinic in MPN and CLL From ASH 2023: Drs Rogers, Brown, and ShammoOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Latest:
Dr. Junker on Need to Identify Biomarkers to Predict Response to RCC TreatmentKerstin Junker, MD, associate professor, Department of Urology, Universit
Latest:
Dr. Badani on the Evolution of Robotic Retroperitoneal Partial Nephrectomies in RCCKetan K. Badani, MD, discusses the evolution of robotic retroperitoneal partial nephrectomies in renal cell carcinoma.
Latest:
Primary Radiation Therapy for Myeloid Sarcoma of the Porta HepatisTreating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.
Latest:
Dr. Kevin Kim on T-VEC in MelanomaKevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses T-VEC as a treatment option for melanoma.
Latest:
Big Data Era Arrives in Clinical Practice Via CancerLinQ ProjectThis new approach—with a focus on personalized, data-driven decisions—is remaking healthcare, and more specifically, changing how oncologists treat cancer.
Latest:
Dr. Harrington on the KEYNOTE-048 Trial in Recurrent/Metastatic Head and Neck CancerKevin Harrington, BSc, MBBS, PhD, MRCP, FRCP, FRCR, discusses the randomized phase 3 KEYNOTE-048 trial in recurrent/metastatic head and neck squamous cell carcinoma.
Latest:
Dr. Hughes on Mutational Risk in OncologyKevin Hughes, MD, discusses mutational risk in oncology.
Latest:
PrimeMD, a Pain Reporting Smartphone Application for Patients Undergoing Head and Neck RadiationA feasibility study of a smartphone application that patients undergoing radiation therapy for head and neck cancer can use to regularly report mucositis symptoms.
Latest:
Dr Kalinsky on Unanswered Questions Regarding Genomic Testing in HR+ Breast CancerKevin Kalinsky, MD, MS, discusses questions regarding the utility and implementation of genomic testing approaches in hormone receptor–positive breast cancer.
Latest:
Dr Kalinsky on the Implications of DESTINY-Breast06 for T-DXd Use in HER2-Ultralow Breast CancerKevin Kalinsky, MD, MS, discusses the phase 3 DESTINY-Breast06 trial evaluating trastuzumab deruxtecan in HER2-expressing breast cancer.
Latest:
Dr. Fox Discusses Genomic Testing in Breast CancerDr. Kevin Fox, from Abramson Cancer Center, Discusses Genomic Testing in Breast Cancer
Latest:
Dr. Kelly on BT062 Combination With Lenalidomide for R/R MyelomaKevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses indatuximab ravtansine (BT062) in combination with lenalidomide (Revlimid) in patients with relapsed or refractory multiple myeloma.
Latest:
Surgical Challenges and Opportunities in Treating Penile CancerKevin R. Loughlin, MD, MBA, discusses the diagnosis, staging, and management of penile cancer.
Latest:
Dr. Hughes on RT in Elderly Patients With ER+ Breast CancerKevin S. Hughes, MD, co-director, Avon Comprehensive Breast Evaluation Center, medical director, Bermuda Cancer Genetics and Risk Assessment Clinic, Harvard Medical School, Massachusetts General Hospital, discusses treatment with radiation therapy for patients with ER-positive breast cancer.
Latest:
Dr. Stephans on Treatment for Oligometastatic Lung CancerKevin Stephans, MD, associate staff, Radiation Oncology at Cleveland Clinic, discusses advancements in the treatment of patients with oligometastatic lung cancer.
